Moreover, blocking pathological interactions involving SQOR is a novel approach–the natural compound iridoside can disrupt GA50’s binding to SQOR, thereby inhibiting NLRP3 inflammasome activation in ALS models (Fu et al., 2023). Here, SQOR is linked to amyotrophic lateral sclerosis.